Souhaitez-vous accéder aux communiqués récents ?

  - Launched Unyvero System and Unyvero LRT Cartridge in the U.S. - Increased revenues to EUR 1.4 million in 2018 - Raised EUR 19.5 million additional funding - Revised focus and strategy ...

Company to host earnings conference call on same day Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 5, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its...

Growing body of evidence shows benefits of Unyvero for antibiotic stewardship8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI Amsterdam, the...

Knowledge base of antimicrobial resistance (AMR) markers tailored specifically to Unyvero ApplicationsDeveloped by Curetis’ subsidiary Ares Genetics and powered by ARESdbInitial focus on Unyvero...

Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 1, 2019, 03:00 pm CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level...

Menarini Diagnostics to distribute Unyvero Platform and application cartridges in numerous European countries Menarini Diagnostics to deploy its commercial team for the marketing of Unyvero...

QIAGEN becomes exclusive partner for bioinformatics research applications based on ARESdb and AREStoolsPartnership intends to create a community platform for antimicrobial resistance research ...

Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China Submission for Unyvero HPN Cartridge to Chinese regulatory authority NMPA includes U.S. and EU dataLeverages...

HPN Cartridge approved in Malaysia; HPN, BCU Cartridges approved in ThailandFurther commercial roll-out of Unyvero in ASEAN region by partner Acumen Research Laboratories facilitatedNear-term...

Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by...